Lucid Diagnostics (LUCD) Debt Ratio (2021)
Lucid Diagnostics posted quarterly Debt Ratio of 6.8 for Q3 2021.
Lucid Diagnostics (LUCD) has 1 years of Debt Ratio data on file, last reported at 6.8 in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 0.31 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 0.32 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.31 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 0.25 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.04 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.25 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 0.27 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 0.18 |
| 10 | Lucid Diagnostics | 145.00 Mn | 117.12 Mn | -325,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 6.80 |